Bal Pharma Q3 FY26 results: Revenue up 20% YoY, Net Profit nearly triples

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

BALPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹72.00

prior close

₹73.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+5.4% vs market

Pharmaceuticals peers, median of 157sector-0.7%+5.6% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Microcap 250 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+3.0

15m

+1.6

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-0.5+5.4-0.7+5.6

Next day

+4.9-2.0+6.9-1.4+6.4

+3.5-2.7+6.2-2.1+5.7

+6.9-1.7+8.7-1.6+8.6

+8.5-1.4+9.9-1.6+10.1

+8.5-2.8+11.3-2.5+11.0

+7.7-2.8+10.5-2.9+10.6

15d

+1.3-8.4+9.7-6.5+7.9

-1.3-9.1+7.8-6.6+5.4

+4.6-4.0+8.6-3.5+8.0

+12.4+2.6+9.8+0.7+11.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bal Pharma reported Q3 FY26 standalone revenue of 8,749 lakhs, up about 20% YoY from 7,289 lakhs. Net profit surged to 195 lakhs from 69 lakhs last year. For 9 months, revenue grew about 3% to 22,688 lakhs while net profit rose around 39% to 305 lakhs. Statutory auditors SSJNB and Co issued an unmodified opinion. Consolidated results also showed improvement.

Likely market impact

Strong Q3 earnings with revenue up 20% and profit nearly tripling YoY, likely to be viewed positively by investors.